Prof. Maoyi Xu | Thoracic Neoplasms | Best Researcher Award

The Affiliated Hospital of Jiaxing University | China

AUTHOR PROFILE

🏫 EARLY ACADEMIC PURSUITS

Maoyi Xu began his academic journey with a Bachelor of Medicine in Clinical Medicine at Jiaxing University (2009–2014). During these formative years, Xu developed a strong foundation in medical sciences and clinical applications, showcasing a keen interest in oncology. This passion led him to pursue advanced education, obtaining a Master of Medicine in Oncology from Dalian Medical University, China, in 2017. His graduate studies were characterized by rigorous research and hands-on training, laying the groundwork for his future career in oncology.

💼 PROFESSIONAL ENDEAVORS

Maoyi Xu’s professional career began with a pivotal role at the Department of Radiotherapy Oncology, Zhuji People’s Hospital of Zhejiang Province (2017–2019), affiliated with Wenzhou Medical University. Here, he honed his skills in radiotherapy and gained invaluable experience treating cancer patients.
In 2019, Xu transitioned to the Department of Oncology at the First Affiliated Hospital of Jiaxing University, where he continues to work. His role involves comprehensive patient care, cutting-edge research, and contributions to the hospital’s oncology department’s growth.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON THORACIC NEOPLASMS

Xu has focused his research on innovative cancer treatment strategies, particularly in radiotherapy and targeted oncology treatments. He is committed to improving patient outcomes by integrating the latest advancements in oncology into clinical practice. Xu’s research bridges the gap between theory and application, enhancing therapeutic methodologies to benefit patients.

🌟 IMPACT AND INFLUENCE

Through his work, Xu has positively influenced oncology practices within Zhejiang Province and beyond. His contributions have led to advancements in radiotherapy techniques and improved patient care protocols. Xu is also a mentor to young professionals, fostering a culture of learning and collaboration.

📊 ACADEMIC CITATIONS

Although Xu’s academic citations are in development, his publications have started to gain recognition in medical circles. His research papers focus on innovative radiotherapy approaches and patient-centered care strategies. These contributions are adding value to the field of oncology.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Maoyi Xu is poised to leave a lasting legacy as a dedicated oncologist and researcher. He envisions a future where his contributions will significantly impact cancer treatment practices and policies, particularly in China. Xu aims to pioneer new research initiatives, foster interdisciplinary collaboration, and improve cancer care at both the local and global levels.

📝 CONCLUSION

Maoyi Xu’s journey from an aspiring medical student to a dedicated oncologist and researcher exemplifies a commitment to excellence and innovation in the field of oncology. His academic pursuits laid a solid foundation for his professional growth, while his clinical and research contributions continue to impact cancer treatment and patient care.

📊🔬NOTABLE PUBLICATION:

The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer
- Authors: Xu, M., Song, B., Yang, X., Li, N.
- Journal: Journal of International Medical Research
- Year: 2022

Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway
- Authors: Song, B., Hou, G., Xu, M., Chen, M.
- Journal: Cellular Signalling
- Year: 2024

Zoledronic acid inhibits the bone metastasis of breast cancer by repressing exosome-loaded DKK1
- Authors: Song, B.B., Xu, M.Y., Xu, X.F., Li, X., Chen, M.
- Journal: Bangladesh Journal of Pharmacology
- Year: 2022

Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study
- Authors: Zhang, Y.-F., Wang, G.-D., Huang, M.-G., Si, J., Xu, M.-Y.
- Journal: World Journal of Gastrointestinal Oncology
- Year: 2023

β-elemene inhibits radiation and hypoxia-induced macrophages infiltration via Prx-1/NF-κB/HIF-1α signaling pathway
- Authors: Yu, X., Li, Z., Zhang, Y., Zou, K., Zou, L.
- Journal: OncoTargets and Therapy
- Year: 2019

EARLY ACADEMIC PURSUITS

Michele Moreau's academic journey began with a Bachelor of Science (B.S.) in Physics from the University of Kentucky in May 2009. Following this foundational degree, Michele pursued a Master of Science (M.S.) in Applied Physics from the Physics Department at the University of Massachusetts Boston, graduating in May 2012. Building upon this, Michele achieved another M.S. in Medical Physics from the Radiological Sciences Department at the University of Massachusetts Lowell in May 2022. These early academic pursuits set the stage for Michele's specialization in the field of biomedical engineering and biotechnology.

PROFESSIONAL ENDEAVORS

During Michele Moreau's academic journey, she served as a Teaching and Research Assistant at the University of Massachusetts Lowell from 2014 to 2023. Her role involved teaching an Introductory Physics Lab course and grading lab reports and quizzes. Furthermore, Michele completed a 6-month internship focused on developing a platform for catalyzing collaborative global Cancer Care Education and Research (CaRE). This initiative aimed to enhance Access to Medical Physics Education and Research Excellence (AMPERE), showcasing her commitment to global health initiatives.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPEUTICS AND NOVEL APPROACHES

Michele Moreau's primary research focus revolves around biomedical research in cancer therapy. As a Graduate Research Trainee from 2015 to 2023 at prestigious institutions such as Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Johns Hopkins School of Medicine, Michele specialized in engineering solid and liquid formulations of smart radiotherapy biomaterials. Her expertise encompasses a wide range of techniques and methodologies, including:Engineering Smart Radiotherapy Biomaterials,Monolayer and 3D Cell Culture etc.,

IMPACT AND INFLUENCE

Michele Moreau's research contributions have the potential to revolutionize cancer therapy by improving the effectiveness of in-situ treatment of tumor masses. Her work on smart radiotherapy biomaterials and associated techniques could significantly enhance the precision and efficiency of cancer treatments, benefiting countless patients worldwide.

ACADEMIC CITES

Michele's research findings and contributions to the field of biomedical engineering and biotechnology have likely been cited in various academic publications, journals, and conferences. Her collaborations with esteemed institutions and her focus on cutting-edge research topics make her a notable figure in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Michele Moreau is expected to be conferred with a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell in August 2023, her legacy in the field is already taking shape. Her multidisciplinary approach to cancer therapy, combining physics, engineering, and biology, paves the way for future advancements in the field. Michele's dedication to improving cancer treatments and her commitment to global health initiatives highlight her potential to leave a lasting impact on biomedical research and patient care.